D-AP5 is a novel and potent NMDA receptor antagonist.

Felbamate (also known as ADD-03055), an antagonist at the NMDA-associated glycine binding site, is an anti-epileptic drug used in the treatment of epilepsy.

PEAQX (also known as NVP-AAM 077) is a novel, potent, orally bioactive and competitive antagonist at the NMDA receptor.

Radiprodil, formerly known as RGH-896, is an orally bioavailable and selective NMDA receptors antagonist which was evaluated as potential treatmen of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).

TCN-201 is a novel, potent, non-competitive and selective antagonist of NMDA receptors containing the NR2A subunit with a pIC50 of 6.8. TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner.

Sarcosine [also called N-methylglycine, Sarcosinic acid, Methylaminoacetic acid, Methylglycine] is a competitive inhibitor of the type I glycine transporter (GlyT1) and an N-methyl-D-aspartate receptor (NMDAR) co-agonist. Sarcosine is a GlyR agonist in addition to being a GlyT1 inhibitor and NMDAR co-agonist, but it is less potent than glycine as a GlyR agonist and is not […]

NMDAR antagonist 1 is a bioavailable NR2B-selective.